Cargando…

Editorial: Secreted proteins as novel biomarkers and therapeutic targets in NAFLD

Detalles Bibliográficos
Autor principal:	Xiong, Xuelian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513454/ https://www.ncbi.nlm.nih.gov/pubmed/37745720 http://dx.doi.org/10.3389/fendo.2023.1277101

Ejemplares similares

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities
por: Du, Xiaomi, et al.
Publicado: (2021)

Editorial: Pharmacology and treatment methods for NAFLD in the context of diabetes
por: Abu-Farha, Mohamed, et al.
Publicado: (2022)

Identification of ribosomal protein family as immune-cell-related biomarkers of NAFLD by bioinformatics and experimental analyses
por: Li, Gerui, et al.
Publicado: (2023)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

Editorial: Novel therapeutic strategy against obesity by targeting thermogenic fat
por: Pan, Ruping, et al.
Publicado: (2022)

Editorial: Novel Biomarkers for Type 2 Diabetes
por: Ahluwalia, Tarunveer S., et al.
Publicado: (2019)

Editorial: The roles and mechanisms of hepatokines, adipokines and myokines in the development of non-alcoholic fatty liver disease (NAFLD)
por: Lu, Yan
Publicado: (2022)

Editorial: Cellular dysfunction and death in diabetes (etio)pathology: Novel insights into molecular mechanisms and therapeutic targeting
por: Markelic, M., et al.
Publicado: (2023)

Galectin-3 in NAFLD: Therapeutic Target or Noncausal Biomarker?
por: Soccio, Raymond E
Publicado: (2021)

Pathways of Glucagon Secretion and Trafficking in the Pancreatic Alpha Cell: Novel Pathways, Proteins, and Targets for Hyperglucagonemia
por: Asadi, Farzad, et al.
Publicado: (2021)

Baseline level and change trajectory of the triglyceride-glucose index in relation to the development of NAFLD: a large population-based cohort study
por: Wang, Yaqin, et al.
Publicado: (2023)

Editorial: Novel biomarkers and extracellular vesicles in endocrine hypertension and related disorders
por: Carvajal, Cristian A., et al.
Publicado: (2023)

Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
por: Zhang, Ziqi, et al.
Publicado: (2023)

Exosomes: Biomarkers and Therapeutic Targets of Diabetic Vascular Complications
por: Chen, Anqi, et al.
Publicado: (2021)

Editorial: Microbiota-hormones-gut axis as a therapeutic target for metabolic disorders
por: Abidi, Anouar, et al.
Publicado: (2023)

Major roles of kupffer cells and macrophages in NAFLD development
por: Park, Soo-Jeung, et al.
Publicado: (2023)

Sensitivity to Thyroid Hormone Indices Are Closely Associated With NAFLD
por: Lai, Shuiqing, et al.
Publicado: (2021)

Editorial: Targeting different programmed cell death processes as therapeutic modalities for thyroid cancer
por: Rajabi, Sadegh
Publicado: (2023)

Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers
por: Ha, Siyoung, et al.
Publicado: (2023)

Editorial: Novel insights into the pathophysiology of diabetes-related complications: Implications for improved therapeutic strategies
por: Ma, Jian, et al.
Publicado: (2023)

Editorial: Male idiopathic infertility: Novel possible targets, volume II
por: Cannarella, Rossella, et al.
Publicado: (2023)

Editorial: Reviews in receptor-receptor interactions as novel targets for drug development
por: Guidolin, Diego, et al.
Publicado: (2023)

Editorial: Male Idiopathic Infertility: Novel Possible Targets, Volume I
por: Cannarella, Rossella, et al.
Publicado: (2021)

Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning
por: Cao, Yang, et al.
Publicado: (2023)

GPR35 as a Novel Therapeutic Target
por: MacKenzie, A. E., et al.
Publicado: (2011)

Myokines: Novel therapeutic targets for diabetic nephropathy
por: Yang, Ming, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

The role of FOXA family transcription factors in glucolipid metabolism and NAFLD
por: Yu, Chuchu, et al.
Publicado: (2023)

Comparative Study of Different Diets-Induced NAFLD Models of Zebrafish
por: Chen, Bo, et al.
Publicado: (2018)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
por: Niu, Shu, et al.
Publicado: (2022)

OR22-07 Novel Variants in Protein Kinase a Signaling-Related Genes Identified in Obese Children with and Without NAFLD
por: Bloyd, Michelle, et al.
Publicado: (2020)

Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases
por: Couvineau, Alain, et al.
Publicado: (2019)

Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans
por: De Sousa-Coelho, A. L., et al.
Publicado: (2023)

Hunger & satiety signals: another key mechanism involved in the NAFLD pathway
por: López-Méndez, Iván, et al.
Publicado: (2023)

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction
por: Guo, Mingwei, et al.
Publicado: (2022)

Crucial role of T cells in NAFLD-related disease: A review and prospect
por: Mao, Tianyu, et al.
Publicado: (2022)

Cancer glycomics offers potential biomarkers and therapeutic targets in the framework of 3P medicine
por: Guo, Yuna, et al.
Publicado: (2022)

Glutamatergic system components as potential biomarkers and therapeutic targets in cancer in non-neural organs
por: García-Gaytán, Ana Cristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rnik2qlvg17pi99u7ajmj6drbs